IMMEDIATE (by July 31, 2026): Billing team must implement claim processing updates for Aetna Tourette's Syndrome cases: (1) REQUIRE prior authorization for all covered services (CBIT, psychotherapy CPT 90832-90840, EEG 95812-95830, E&M 99201-99215) using CPB 0480 selection criteria validation (multiple motor + vocal tics, >1 year duration, onset <age 18, no substance/medical cause); (2) DENY or redirect to experimental review all claims for CPT codes 0042T, 0648T, 0649T, 61735, 61863-61868, 61880, 61885-61888, 64612, 64616-64617, and 70450, 70460, 70470, 70472-70473, 70496 when used for Tourette's diagnosis/treatment; (3) UPDATE billing software and encounter forms to flag Tourette's cases for medical necessity documentation review before claim submission; (4) COMMUNICATE to neurology, psychiatry, and behavioral health providers that pharmacotherapy (aripiprazole, clonazepam, clonidine, haloperidol, pimozide, risperidone, tetrabenazine, tricyclic antidepressants) coverage requires referral to pharmacy benefit plan, not medical billing; (5) DOCUMENT that educational interventions are non-covered under most Aetna plans and should not be billed. Failure to implement prior authorization requirements will result in claim denials; submission of experimental codes without proper denial management will trigger audit liability.